176 related articles for article (PubMed ID: 22676385)
1. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.
Linley WG; Hughes DA
Pharmacoeconomics; 2012 Sep; 30(9):779-94. PubMed ID: 22676385
[TBL] [Abstract][Full Text] [Related]
2. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
[TBL] [Abstract][Full Text] [Related]
3. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
Linley WG; Hughes DA
Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
[TBL] [Abstract][Full Text] [Related]
4. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
5. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
Malinowski KP; Kawalec P; Trąbka W
Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
[TBL] [Abstract][Full Text] [Related]
6. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
7. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
Wallerstedt SM; Henriksson M
Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
[TBL] [Abstract][Full Text] [Related]
8. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
9. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
12. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
13. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
14. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
15. Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group.
Keeping S; Deslandes PN; Haines KE; Routledge PA
Pharmacoecon Open; 2019 Sep; 3(3):343-350. PubMed ID: 30656545
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
17. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
[TBL] [Abstract][Full Text] [Related]
18. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand.
Teerawattananon Y; Tritasavit N; Suchonwanich N; Kingkaew P
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):397-404. PubMed ID: 25444298
[TBL] [Abstract][Full Text] [Related]
19. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]